Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF, FRA:DDF) has been granted a trading halt by the ASX with news of a proposed capital raising pending.
The halt will remain in place until the start of regular trading on Monday, August 2, or until an announcement is released to the market, whichever occurs earliest.
Patent granted
The company has recently been granted a patent for its ‘Sterilized packaging system for catheter’ invention by the Commonwealth of Australia Patent Office.
Sterilization of surgical products used in vivo is essential, and having a specialised, proprietary sterilization system enhances the intellectual property barrier around Anteris’ key technologies particularly for its ComASUR transfemoral delivery system and maintains product sterile status in the delivery chain from manufacturing point to surgical theatre.
The patent will help protect against potential product counterfeit and adds to product commercial value.
ComASUR is a commissural alignment device that can help surgeons most accurately position the heart valve, which expands like a balloon when it is put in place.